ABIO 3419
Alternative Names: ABIO-3419Latest Information Update: 05 Jul 2024
At a glance
- Originator Symatese
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Osteoarthritis
Most Recent Events
- 18 Jan 2024 Clinical trials in Osteoarthritis in Latvia (Intra-articular) (NCT06097988)
- 24 Oct 2023 Preclinical trials in Osteoarthritis in France (Intra-articular) (NCT06097988)
- 24 Oct 2023 Symatese plans a phase I (PILHAC) trial for Knee Osteoarthritis in January 2024 (NCT06097988)